Search Results
33 protocol(s) meet the specified criteria
100288Open  
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: Phase III Prospective Randomized Trial

100290Open  
Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine ResponsIVE Breast Cancer (POSITIVE)

101274Not Open *
Phase I Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects with Advanced Solid Tumors likely to Express Prolactin Receptor (PRLR)

103657Open  
Exploratory Phase IB Study to Assess the Effects of Merestinib on Bone Metastases in Subjects with Breast Cancer

103976Open  
Phase II Trial of a 9-Day Course of Whole Breast Radiotherapy for Early Stage Breast Cancer

104258Open  
Phase I/II, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors

104260Open  
SHERBOC: Double-Blind, Placebo-Controlled, Phase II Trial of Seribantumab plus Fulvestrant in Postmenopausal Women with Hormone Receptor-Positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer whose Disease Progressed after Prior Systemic Therapy

104630Open  
Phase I Dose Escalation Study Evaluating the Safety and Tolerability of PF-06804103 in Patients with Human Epidermal Growth Factor Receptor 2 (HER2) Positive Solid Tumors (FIM)

105517Open  
Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery

105539Open  
Phase II Randomized, Double-Blinded, Controlled Study of Tucatinib versus Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)

105691Open  
Nonpharmacologic Interventions for Fatigue in Patients with Cancer

107224Open  
Randomized Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy

109281Open  
Open Label, Phase II Trial of Neoadjuvant Tak-228 plus Tamoxifen in Patients with Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor Type 2 (HER2)-Negative Breast Cancer

109583Open  
Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction

109587Not Open *
Phase II Multiple-Arm, Open-Label, Randomized Study of PARP Inhibition (Veliparib) and Anti-PD-L1 Therapy (Atezolizumab) either Alone or in Combination in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC)

30321Open  
Non-Invasive, Image-Guided, High-Intensity Focused Ultrasound (HIFU) for Breast Cancer Therapy

69515Open  
Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment

76139Open  
Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy

76853Open  
Phase I/IB Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

77671Open  
Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes after Neoadjuvant Chemotherapy

81405Open  
Phase I/IIA Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

82831Open  
Phase I/II, Open-Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination with PDR001 Administered to Patients with Advanced Malignancies

85602Open  
Randomized Phase III Trial of Adjuvant Therapy comparing Doxorubicin plus Cyclophosphamide followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

87559Open  
Phase I/II Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer

88099Open  
Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer (PALbociclib CoLlaborative Adjuvant Study, PALLAS)

94144Open  
Phase IB, Open-Label, Multicenter Study to Characterize the Safety, Tolerability, and Pharmacodynamics (PD) of PDR001 in Combination with LCL161, Everolimus (RAD001), or Panobinostat (LBH589)

94979Open  
Study to Identify Predictors of Response to Duloxetine in Breast Cancer Patients with Chronic Pain

95172Open  
Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

95175Open  
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (BWEL)

99038Open  
Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer

99137Open  
Randomized Phase III Double-Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial

99894Open  
Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib plus Anti-HER2 Therapy plus Endocrine Therapy versus Anti-HER2 Therapy plus Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

99906Open  
Phase I Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors